News
NeuroOne (Nasdaq:NMTC) announced today that it filed an FDA 510(k) submission for its trigeminal nerve ablation technology.
The following is a summary of “Suicidal Ideation and Self-Injury in Trigeminal Neuralgia,” published in the April 2025 issue ...
NeuroOne submits FDA filing early for trigeminal nerve ablation using its OneRF system as the facial pain market sees projected growth to $416 million by 2030.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback